• 24
    Jul, 2025

    Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.

Ready to talk?

Lorem ipsum dolor sit amet, consectetur adipisicing elit mod tempor incididunt ut labore et dolore magna aliqua.